Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 65683 

1 15 U.S.C. 3051 through 3060. 

2 16 CFR 1.142. 

NYSHEX technology council meetings, 

and other discussions relevant to the 

management of NYSHEX in addition to 

participating in NYSHEX Board 

meetings. The Amended would also 

remove Ocean Network Express Pte. 

Ltd. (ONE) and add Mediterranean 

Shipping Company SA. 

Proposed Effective Date: 10/30/2023. 

Location: https://www2.fmc.gov/ 

FMC.Agreements.Web/Public/ 

AgreementHistory/2064. 

Dated: September 20, 2023. 

Carl Savoy, 

Federal Register Alternate Liaison Officer, 

Federal Maritime Commission. 

[FR Doc. 2023–20674 Filed 9–22–23; 8:45 am] 

BILLING CODE 6730–02–P 

FEDERAL MARITIME COMMISSION 

[Docket No. 23–05] 

Rahal International Inc., Complainant 

v. Hapag-Lloyd AG, Hapag-Lloyd 

(America), LLC, and Hapag-Lloyd USA, 

LLC, Respondents and Third-Party 

Complainants v. Maher Terminals, 

LLC, GCT New York LP, and GCT 

Bayonne LP, Third-Party Respondents; 

Notice of Filing of Third-Party 

Complaint; Correction 

AGENCY: Federal Maritime Commission. 

ACTION: Notice; correction. 

SUMMARY: On September 8, 2023, the 

Federal Maritime Commission (FMC) 

published a document in the Federal 

Register of September 15, 2023, 

concerning a third-party complaint filed 

in Docket No. 23–05. This document 

incorrectly designated Hapag-Lloyd 

USA, LLC as a Third-Party 

Complainant. 

FOR FURTHER INFORMATION CONTACT: 

Amy Strauss, Acting Secretary, (202) 

523–5725 or secretary@fmc.gov. 

SUPPLEMENTARY INFORMATION: In the 

Federal Register of September 15, 2023, 

on page 63575: 

1. in the first column remove the 

document title and replace with the 

following: Rahal International Inc., 

Complainant v. Hapag-Lloyd AG, 

Hapag-Lloyd (America), LLC, and 

Hapag-Lloyd USA, LLC, Respondents 

and Hapag-Lloyd AG and Hapag-Lloyd 

(America), LLC, Third-Party 

Complainants v. Maher Terminals, LLC, 

GCT New York LP, and GCT Bayonne 

LP, Third-Party Respondents; Notice of 

Filing of Third-Party Complaint 

2. in the second column, both times 

it appears, remove ‘‘Hapag-Lloyd AG, 

Hapag-Lloyd (America), LLC, and 

Hapag-Lloyd USA, LLC’’ and replace 

with the following: Hapag-Lloyd AG 

and Hapag-Lloyd (America), LLC 

3. in the second column, remove the 

following paragraph: Respondent and 

Third-Party Complainant Hapag-Lloyd 

USA, LLC is a United States subsidiary 

and agent of Hapag-Lloyd AG with its 

office located in Atlanta, Georgia. 

Carl Savoy, 

Federal Register Alternate Liaison Officer, 

Federal Maritime Commission. 

[FR Doc. 2023–20642 Filed 9–22–23; 8:45 am] 

BILLING CODE 6730–02–P 

FEDERAL TRADE COMMISSION 

[File No. P222100] 

Horseracing Integrity and Safety 

Authority Anti-Doping and Medication 

Control Rule Modification 

AGENCY: Federal Trade Commission 

ACTION: Notice of Horseracing Integrity 

and Safety Authority (HISA) proposed 

rule modification; request for public 

comment. 

SUMMARY: As required by the 

Horseracing Integrity and Safety Act of 

2020, the Federal Trade Commission 

(‘‘FTC’’ or ‘‘Commission’’) publishes a 

proposed rule modification related to 

the equine Anti-Doping and Medication 

Control Program of the Horseracing 

Integrity and Safety Authority (‘‘HISA’’ 

or the ‘‘Authority’’). Specifically, the 

proposed rule modification would 

designate iron dextran as a banned 

substance and thereby prohibit its use. 

This publication contains the 

Authority’s proposed rule’s text and 

explanation, and it seeks public 

comment on whether the Commission 

should approve the proposed rule. 

DATES: The Commission must approve 

or disapprove the proposed 

modification on or before November 24, 

2023. If approved, the proposed rule 

modification would be effective 

immediately. Comments must be filed 

on or before October 10, 2023. 

ADDRESSES: Interested parties may file a 

comment online or on paper by 

following the instructions in the 

Request for Comment part of the 

SUPPLEMENTARY INFORMATION section. 

Write ‘‘HISA Anti-Doping and 

Medication Control Rule Modification’’ 

on your comment and file your 

comment online at https://

www.regulations.gov by following the 

instructions on the web-based form. If 

you prefer to file your comment on 

paper, mail your comment to the 

following address: Federal Trade 

Commission, Office of the Secretary, 

600 Pennsylvania Avenue NW, Suite 

CC–5610 (Annex H), Washington, DC 

20580. 

FOR FURTHER INFORMATION CONTACT: John 

H. Seesel (202–326–2702), Associate 

General Counsel, Office of the General 

Counsel, Federal Trade Commission, 

600 Pennsylvania Avenue NW, 

Washington, DC 20580. 

SUPPLEMENTARY INFORMATION: On July 8, 

2023, pursuant to section 3053(a) of the 

Horseracing Integrity and Safety Act of 

2020 (‘‘Act’’) 1 and FTC Rule 1.142,2 the 

Horseracing Integrity and Safety 

Authority (‘‘HISA’’ or the ‘‘Authority’’) 

filed with the Commission a proposed 

modification of the Authority’s antidoping rules to include iron dextran as 

a banned substance. Sections I and II 

below set forth the Authority’s proposal. 

The Commission is publishing this 

document to solicit comments on the 

proposed rule modification from 

interested persons. 

The proposed modification would 

insert the following row for Iron Dextran 

into the ‘‘Technical Document— 

Prohibited Substances’’ appendix to the 

Prohibited List (Rule Series 4000), 

between the row for Irbesartan and the 

row for Isoaminile. 


ddrumheller on DSK120RN23PROD with NOTICES1
65684 Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 

3See FTC, HISA Anti-Doping and Medication 

Control Rule, 88 FR 5070 (Jan. 26, 2023). 

4Order Approving the Anti-Doping and 

Medication Control Rule Proposed by the 

Horseracing Integrity and Safety Authority (Mar. 27, 

2023), https://www.ftc.gov/system/files/ftc_gov/pdf/ 

P222100CommissionOrder

AntiDopingMedication.pdf. 

5 Iron dextran is colloquially referred to as ‘‘pig 

iron.’’ 

6Those exhibits are available as a supporting 

document on the docket for this matter at https:// 

www.regulations.gov. 

HISA listed as HISA status 

Penalty subclassification 

(specified Substances 

are designated with ‘x’) 

Substance Action 

Commercial 

name(s) 

(developmental names) 

Detection time 

Screening limit (unless 

otherwise designated 

as a threshold). 

Where no value is listed for serum or plasma 

the substance 

*******

BANNED ........... S6 ......................................... Iron Dextran, 

Colloquial 

Name: Pig 

Iron.

Iron deficiency 

anemia treatment.

Nonemic, 

Ferrextran, 

Imposil, 

Uniferon.

*******

* * * * * 

I. Self-Regulatory Organization’s 

Statement of the Background, Purpose 

of, and Statutory Basis for the Proposed 

Rule Modification 

The Horseracing Integrity and Safety 

Act of 2020 recognizes that the 

establishment of a national set of 

uniform standards for racetrack safety 

and medication control will enhance the 

safety and integrity of horseracing. The 

Act mandates and empowers the 

Authority to establish a uniform antidoping and controlled medication 

program (‘‘ADMC Program’’) to improve 

the integrity and safety of horseracing in 

the United States. The Authority 

developed the proposed rules that 

constitute the ADMC Program and filed 

the proposed rules with the Commission 

on December 28, 2022. The proposed 

rules were published in the Federal 

Register on January 26, 2023,3 and were 

subsequently approved by the 

Commission by Order dated March 27, 

2023.4

As part of the ADMC Program, the 

Authority developed the Rule Series 

4000 Prohibited List. This includes a list 

of permitted and prohibited 

medications, substances, and methods, 

including allowable limits of permitted 

medications, substances, and methods. 

The Prohibited List uses as a baseline 

the lists of permitted and prohibited 

substances (including drugs, 

medications, and naturally occurring 

substances and synthetically occurring 

substances) in effect for the 

International Federation of Horseracing 

Authorities (‘‘IFHA’’), including the 

IFHA International Screening Limits for 

urine and the IFHA International 

Screening Limits for plasma. 

The Prohibited List identifies 

Prohibited Substances and Prohibited 

Methods that are: (a) prohibited at all 

times (‘‘Banned Substances’’ and 

‘‘Banned Methods’’) on the basis of the 

Authority’s determination that medical, 

veterinary, or other scientific evidence 

or experience supports their actual or 

potential (i) ability to enhance the 

performance in Covered Horses, (ii) 

masking properties, or (iii) detrimental 

impact on horse welfare; or (b) 

prohibited for Use on or Administration 

to a Covered Horse during the Race 

Period and prohibited to be present in 

a Post-Race Sample (which includes 

samples collected following a Covered 

Horserace or Vets’ List Workout) or 

Post-Work Sample (which includes 

samples collected following a Timed 

and Reported Workout), except as 

otherwise specified in the Prohibited 

List (‘‘Controlled Medication 

Substances’’ and ‘‘Controlled 

Medication Methods’’). Prohibited 

Substances and Prohibited Methods 

may be included in the Prohibited List 

by general category (e.g., anabolic 

steroids) or by specific reference to a 

particular substance or method. 

The ‘‘Technical Document— 

Prohibited Substances’’ (‘‘Technical 

Document’’), as an appendix to the 

Prohibited List (Rule Series 4000), 

supplements the Prohibited List and 

sets out additional detail concerning 

Prohibited Substances. The Technical 

Document enumerates specific 

Prohibited Substances that fall into the 

general categories listed in the 

Prohibited List and sets forth detection 

times, screening limits, and thresholds 

for those Prohibited Substances. The 

Technical Document also designates 

certain Prohibited Substances as 

Specified Substances, which are those 

that pose a higher risk of being the 

result of contamination and that are 

therefore subject to more flexible 

sanctions. The Authority proposes to 

modify the Technical Document to add 

iron dextran as a Banned Substance 

(S6).5 The proposed rule modification is 

described in detail in Section II of this 

publication. 

In compliance with 16 CFR 1.142(a), 

the Authority states that the reason for 

adopting the proposed rule modification 

is to protect Covered Horses against the 

use of iron dextran. Use of iron dextran 

poses significant risks to the safety and 

welfare of Covered Horses, as outlined 

in the supporting documentation it 

attached as exhibits to its submission to 

the FTC.6 The designation of iron 

dextran as a Banned Substance will 

prohibit the use of iron dextran in 

Covered Horses. 

The Authority is careful to consider 

all reasonable alternatives to a proposed 

rule modification. In this case, however, 

the obvious and only course available to 

protect Covered Horses from the hazards 

involved in the use of iron dextran is to 

ban its use. 

The Equine Anti-Doping and 

Controlled Medication Protocol 

(‘‘Protocol’’) will affect Covered Persons, 

Covered Horses, and Covered 

Horseraces. The proposed rule 

modification will help to ensure that 

Covered Horseraces are conducted in a 

manner that is consistent with the 

highest standards of integrity and that 

prioritizes the safety of Covered Horses 

and Covered Persons. The welfare of 

Covered Horses will be secured by a 

rule that strictly prohibits the 

administration and possession of iron 

dextran, by categorizing it as a Banned 

Substance (S6). All Covered Persons 

will be subject to sanctions set forth in 

the Rule 3000 Series for failure to 

comply with the new ban. 

To ensure this proposed rule 

modification is consistent with the Act 

and the rules and regulations applicable 

to the Authority, the Authority took the 

following principles and mandates into 

consideration. In accordance with 15 

U.S.C. 3055(a)(2), which directs the 

Authority to consider the unique 

characteristics of any breed made 

subject to the Act by election of a State 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 65685 

7Those seven factors are: (1) ‘‘Covered Horses 

should compete only when they are free from the 

influence of medications, other foreign substances, 

and methods that affect their performance’’; (2) 

‘‘Covered Horses that are injured or unsound 

should not train or participate in Covered 

Horseraces, and the use of medications, other 

foreign substances, and treatment methods that 

mask or deaden pain in order to allow injured or 

unsound horses to train or race should be 

prohibited’’; (3) ‘‘Rules, standards, procedures, and 

protocols regulating medication and treatment 

methods for Covered Horses and Covered 

Horseraces should be uniform and uniformly 

administered nationally’’; (4) ‘‘Consideration 

should be given to international anti-doping and 

medication control standards of the IFHA and the 

Principles of Veterinary Medical Ethics of the 

American Veterinary Medical Association’’; (5) 

‘‘The administration of medications and treatment 

methods to Covered Horses should be based upon 

an examination and diagnosis that identifies an 

issue requiring treatment for which the medication 

or method represents an appropriate component of 

treatment’’; (6) ‘‘The amount of therapeutic 

medication that a Covered Horse receives should be 

the minimum necessary to address the diagnosed 

health concerns identified during the examination 

and diagnostic process’’; and (7) ‘‘The welfare of 

Covered Horses, the integrity of the sport, and the 

confidence of the betting public require full 

disclosure to regulatory authorities regarding the 

administration of medications and treatments to 

Covered Horses.’’ See the supporting documents on 

the docket at www.regulations.gov for the 

Authority’s complete discussion of how these 

factors relate to the proposed rule modification 

concerning iron dextran. 

8Letter to HISA from Dionne Benson, DVM, JD, 

Chief Veterinary Officer for The Stronach Group, 

available among the supporting documents at 

www.regulations.gov. 

9Supporting documents referenced in this 

publication can be found in the public docket for 

this publication on www.regulations.gov. 

10See Natalie Voss, As Gulfstream Prohibits 

Injectable Iron, a Look at the Use of ‘‘Iron Shots,’’ 

Paulick Report (Jan. 12, 2023), available at https:// 

paulickreport.com/horse-care-category/asgulfstream-prohibits-injectable-iron-a-look-at-theuse-of-iron-shots/. 

Racing Commission or breed governing 

organization, the Authority notes that 

proposed rule modification is applicable 

only to Thoroughbred horses, because 

other breeds are not currently subject to 

the jurisdiction of the Authority as 

Covered Horses. The supporting 

documentation submitted to the 

Commission along with this proposed 

rule modification sets forth the need for 

the prohibition of iron dextran because 

of its documented effect upon 

Thoroughbred horses in particular. In 

developing the proposed rule 

modification, the Authority accounted 

for the unique characteristics of 

Thoroughbred horses. 

The Authority also considered the 

seven factors set forth in 15 U.S.C. 

3055(b) and concluded that they 

support the addition of iron dextran to 

the list of Prohibited Substances.7

With reference to the baseline 

standards in 15 U.S.C. 3055(g)(2)(a), 

none of them address the regulation of 

iron dextran. The proposed rule 

modification would not render any rule 

in the Protocol less stringent than 

previously, because no rule in the 

Protocol currently addresses the 

regulation of iron dextran. 

Due to the need to act quickly to 

preserve the safety of Covered Horses, 

the Authority did not solicit informal 

public comments in advance of 

submitting this proposed rule 

modification to the Commission. 

However, the Authority did consult 

with Dr. Dionne Benson, Chief 

Veterinary Officer for The Stronach 

Group, whose letter in support of the 

proposed rule modification 8 can be 

found in the supporting documents 

section of the public docket for this 

publication on www.regulations.gov. 

With the review, input, and ultimate 

approval of the Authority’s Board of 

Directors, the proposed rule 

modification to the Rule 4000 Series 

Technical Document is submitted for 

Commission approval. As required by 

15 U.S.C. 3053(b)(2), the proposed rule 

modification is consistent with the Act 

and the rules approved by the 

Commission. The Authority has 

consulted with the Horseracing Integrity 

and Welfare Unit (‘‘HIWU’’), the antidoping and medication control 

enforcement agency with which the 

Authority has contracted to enforce the 

Protocol pursuant to 15 U.S.C. 

3054(e)(1)(b). The HIWU has 

participated in the development of the 

proposed rule modification and 

approves of it. 

II. Self-Regulatory Organization’s 

Statement of the Terms of Substance of 

the Proposed Rule Modification 

The Authority submits the proposed 

rule modification to the Technical 

Document to designate iron dextran and 

other iron dextran containing products 

as Banned Substances under the ADMC 

Program. 

The risk of serious and potentially 

fatal adverse reactions to iron dextran 

products, together with its testing 

limitations, presents a risk of misuse 

and abuse in Covered Horses. Iron 

dextran products have Food and Drug 

Administration (‘‘FDA’’) approval only 

for the treatment and prevention of irondeficiency anemia in swine. Iron and 

other blood-building supplements 

nonetheless are often administered to 

horses to maximize red blood cell count, 

with the belief that they will improve 

energy, stamina, and athletic 

performance. While the Animal 

Medicinal Drug Use Clarification Act of 

1994, 21 U.S.C. 360b, is permissive of 

the extralabel use of FDA-approved 

products, the documented health risk of 

iron dextran to Covered Horses warrants 

its designation as a Banned Substance 

under the ADMC Program. 

Iron dextran carries an increased risk 

of anaphylaxis and death in 

Thoroughbred racehorses, which has 

prompted some racetracks to ban 

possession of these substances. See 

Benson Letter at 1, supra (‘‘Gulfstream 

Park and Palm Meadows recently 

prohibited the possession and/or use of 

injectable iron and injectable iron 

containing substances on track property. 

This occurred following the sudden 

death of several horses in the past two 

years across all Stronach Group 

properties shortly after they had been 

administered injectable iron 

supplements.’’); see also Thomas Tobin, 

MRCVS, Steven G. Kamerling, Ph.D., 

Iron: Its Functions and Metabolism in 

the Horse, 1986 (‘‘Iron dextran 

injections should not be used to 

supplement iron. One author reported 

that two Thoroughbreds died within 15 

hours of parenteral iron dextran 

injections, and in another case three 

horses died after the intramuscular 

injection of iron dextran. Similarly, the 

administration of supplements 

containing iron to neonatal foals has 

been suggested as a cause of death.’’).9

Iron dextran may also pose a risk to a 

horse’s tissues and immune system. See 

Tobin et al., supra. Oral iron 

supplementation has not been 

associated with the same risk of 

anaphylaxis in horses as intramuscular 

injections.10

Further, to the extent anemia occurs 

in horses, it is likely associated with 

blood loss or an underlying health 

condition, as opposed to a primary iron 

deficiency. Thus, equine veterinary 

experts recommend identifying and 

treating the source of the anemia before 

administering an iron supplement and 

returning the horse to racing and 

training activities only after the anemia 

and its cause have resolved. See Benson 

Letter, supra. 

Finally, monitoring and testing for 

iron dextran products in Covered Horses 

pose significant challenges, as iron is an 

endogenous mineral in the body. See 

Benson Letter, supra. Thus, it is critical 

that possession of iron dextran products 

be prohibited under the rules. By 

categorizing iron dextran as a Banned 

Substance under the ADMC Program, it 

will be prohibited under the Rule 3000 

Series. 

All the changes in the proposed rule 

modification are intended to enhance 

the Rule 4000 Series Technical 

Document in a manner consistent with 

the Act. The proposed rule modification 


ddrumheller on DSK120RN23PROD with NOTICES1
65686 Federal Register / Vol. 88, No. 184 / Monday, September 25, 2023 / Notices 

is carefully tailored to the unique 

character of horseracing and to the 

regulation of Prohibited Substances in 

Covered Horses. 

III. Date of Effectiveness of the 

Proposed Rule Change and Timing for 

Commission Action 

The Commission must approve or 

disapprove the proposed modification 

on or before November 24, 2023. If 

approved, the proposed rule 

modification would be effective 

immediately. 

IV. Request for Comment 

You can file a comment online or on 

paper. For the Commission to consider 

your comment, we must receive it on or 

before October 10, 2023. Write ‘‘HISA 

Anti-Doping and Medication Control 

Rule Modification’’ on your comment. 

Your comment—including your name 

and your state—will be placed on the 

public record of this proceeding, 

including the https://

www.regulations.gov website. 

Postal mail addressed to the 

Commission is subject to delay due to 

heightened security screening. As a 

result, we strongly encourage you to 

submit your comments online. To make 

sure the Commission considers your 

online comment, you must file it at 

https://www.regulations.gov, by 

following the instructions on the webbased form. 

If you file your comment on paper, 

write ‘‘HISA Anti-Doping and 

Medication Control Rule Modification’’ 

on your comment and on the envelope, 

and mail your comment to the following 

address: Federal Trade Commission, 

Office of the Secretary, 600 

Pennsylvania Avenue NW, Suite CC– 

5610 (Annex H), Washington, DC 20580. 

If possible, please submit your paper 

comment to the Commission by 

overnight service. 

Because your comment will be placed 

on the publicly accessible website at 

https://www.regulations.gov, you are 

solely responsible for making sure your 

comment does not include any sensitive 

or confidential information. In 

particular, your comment should not 

include any sensitive personal 

information, such as your or anyone 

else’s Social Security number; date of 

birth; driver’s license number or other 

state identification number, or foreign 

country equivalent; passport number; 

financial account number; or credit or 

debit card number. You are also solely 

responsible for making sure your 

comment does not include any sensitive 

health information, such as medical 

records or other individually 

identifiable health information. In 

addition, your comment should not 

include any ‘‘any trade secret or any 

commercial or financial information 

. . . which is privileged or 

confidential.’’ 15 U.S.C. 46(f); see FTC 

Rule 4.10(a)(2), 16 CFR 4.10(a)(2). In 

particular, your comment should not 

include competitively sensitive 

information such as costs, sales 

statistics, inventories, formulas, 

patterns, devices, manufacturing 

processes, or customer names. 

Comments containing material for 

which confidential treatment is 

requested must be filed in paper form, 

must be clearly labeled ‘‘Confidential,’’ 

and must comply with FTC Rule 4.9(c), 

16 CFR 4.9(c). In particular, the written 

request for confidential treatment that 

accompanies the comment must include 

the factual and legal basis for the 

request and must identify the specific 

portions of the comment to be withheld 

from the public record. See FTC Rule 

4.9(c), 16 CFR 4.9(c). Your comment 

will be kept confidential only if the 

General Counsel grants your request in 

accordance with the law and the public 

interest. Once your comment has been 

posted publicly at https://

www.regulations.gov, as legally required 

by FTC Rule 4.9(b), 16 CFR 4.9(b), we 

cannot redact or remove your comment, 

unless you submit a confidentiality 

request that meets the requirements for 

such treatment under FTC Rule 4.9(c), 

16 CFR 4.9(c), and the General Counsel 

grants that request. 

Visit the FTC website to read this 

publication and the news release 

describing it. The FTC Act and other 

laws the Commission administers 

permit the collection of public 

comments to consider and use in this 

proceeding as appropriate. The 

Commission will consider all timely 

and responsive public comments it 

receives on or before October 10, 2023. 

For information on the Commission’s 

privacy policy, including routine uses 

permitted by the Privacy Act, see 

https://www.ftc.gov/site-information/ 

privacy-policy. 

April J. Tabor, 

Secretary. 

[FR Doc. 2023–20631 Filed 9–22–23; 8:45 am] 

BILLING CODE 6750–01–P 

GENERAL SERVICES 

ADMINISTRATION 

[Notice–Q–2023–04; Docket No. 2023–0002; 

Sequence No. 33] 

Federal Secure Cloud Advisory 

Committee; Notification of Upcoming 

Meeting 

AGENCY: Federal Acquisition Service 

(Q), General Services Administration 

(GSA). 

ACTION: Meeting notice. 

SUMMARY: As stipulated by the Federal 

Advisory Committee Act (FACA), GSA 

is hereby giving notice of a series of four 

(4) open public meetings of the Federal 

Secure Cloud Advisory Committee 

(FSCAC). Information on attending and 

providing public comment is under the 

SUPPLEMENTARY INFORMATION section. 

DATES: The open public meetings will 

be held on Thursday, October 19, 2023, 

from 1:00 p.m. to 3:00 p.m., Eastern 

Daylight Time (EDT); Thursday, October 

26, 2023, from 1:00 p.m. to 3:00 p.m., 

EDT; Thursday, November 2, 2023, from 

1:00 p.m. to 3:00 p.m., EDT; and 

Thursday, November 9, 2023, from 1:00 

p.m. to 3:00 p.m., EST. The agendas for 

the meetings will be made available 

prior to the October 19, 2023 meeting 

online at https://gsa.gov/fscac. 

ADDRESSES: The meetings will be 

accessible via webcast. Registrants will 

receive the webcast information before 

the meeting. 

FOR FURTHER INFORMATION CONTACT: 

Michelle White, Designated Federal 

Officer (DFO), FSCAC, GSA, 703–489– 

4160, fscac@gsa.gov. Additional 

information about the Committee, 

including meeting materials and 

agendas, will be available online at 

https://gsa.gov/fscac. 

SUPPLEMENTARY INFORMATION: 

Background 

GSA, in compliance with the 

FedRAMP Authorization Act of 2022, 

established the FSCAC, a statutory 

advisory committee in accordance with 

the provisions of FACA (5 U.S.C. 10). 

The Federal Risk and Authorization 

Management Program (FedRAMP) 

within GSA is responsible for providing 

a standardized, reusable approach to 

security assessment and authorization 

for cloud computing products and 

services that process unclassified 

information used by agencies. 

The FSCAC will provide advice and 

recommendations to the Administrator 

of GSA, the FedRAMP Board, and 

agencies on technical, financial, 

programmatic, and operational matters 

regarding the secure adoption of cloud 


ddrumheller on DSK120RN23PROD with NOTICES1